Big technology drove the Nasdaq Composite to a weekly gain as the Dow Jones Industrial Average and Russell 2000 both closed the week in negative territory.

The Nasdaq Composite jumped 1.18% on the day to close at 27,188.02, posting a weekly gain of 0.44% as chip and software names led the advance.

The Dow Jones Industrial Average finished at 51,094.96, up 0.33% on the day but down 1.42% for the week, with an RSI14 of 38.1 signaling a weakening trend.

The S&P 500 settled at 7,719.34, gaining 0.69% on Friday but slipping 0.31% for the week, while the Russell 2000 rose 0.97% on the day to 2,833.74 but edged down 0.13% for the week.

The CBOE Volatility Index fell to 15.58, down 0.81 on the day, while WTI crude oil dropped 2.48% on the day and 2.19% for the week to settle at $90.57 a barrel.

Gold eased 0.85% on the day to $4,166.60 an ounce, silver fell to $60.40, and the US 10-year Treasury yield rose 8 basis points for the week to 5.26%.

RTX (NYSE: RTX) saw its Raytheon division secure a five-year contract with two additional option years valued at up to $24.4 billion for Standard Missile-6 interceptors for the U.S. Navy.

Phil Jasper, Raytheon President, said: “SM-6’s multi-mission capability is vital to our customer, and Raytheon is intensely focused on meeting the demand.”

Integra LifeSciences Holdings Corporation (NASDAQ: IART) provided preliminary third-quarter results, citing ongoing impact from a July flooding event at its Cincinnati facility, with expected revenue of approximately $410 million to $412 million.

Stuart Essig, Chairman and Chief Executive Officer, said: “Our third quarter results were impacted by the July flooding event at our Cincinnati facility. Our teams have made significant progress executing recovery plans and supporting customers.”

IART lowered its full-year 2026 revenue outlook to $1.634 billion to $1.654 billion and cut adjusted EPS guidance to $2.30 to $2.40, while still targeting $190 million to $200 million in operating cash flow.

Trilogy Metals Inc. (NYSE American: TMQ) reported a cash balance of $31.2 million as of August 31, 2026, and announced the closing of a $35.6 million strategic equity investment from the Department of War on September 11, 2026.

Tony Giardini, President and CEO of Trilogy Metals, said: “The third quarter and the weeks that followed have been transformational for Trilogy Metals.”

Phillips Edison and Company, Inc. (NASDAQ: PECO) reaffirmed its full-year 2026 earnings guidance and raised its gross acquisitions target to $600 million to $700 million after acquiring $459.7 million in assets year to date through September 30, 2026.

Jeff Edison, Chairman and Chief Executive Officer, said: “We’re pleased to reaffirm our guidance for full year 2026 Core FFO per share growth, which reflects 6.2% year-over-year growth at the midpoint.”

Axogen, Inc. (NASDAQ: AXGN) completed its acquisition of BioCircuit Technologies, adding NerveTape, described as the first FDA cleared device for sutureless peripheral nerve repair.

Michael Dale, President and Chief Executive Officer of Axogen, said: “NerveTape represents a new standard of care as the first sutureless nerve repair option, one that is simpler, faster, and more effective than microsuturing.”

Axogen expects BioCircuit to contribute approximately $6 million to fourth-quarter 2026 revenue and approximately $34 million to 2027 revenue, with the company maintaining its full-year 2026 guidance of at least 24% revenue growth.